GlassScriptPhysician profile
William T Sargent
NPI 1063452340
$4,054.70
in general payments reported to CMS, 2019-2025
28 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $493 · 2021: $644 · 2022: $830 · 2023: $737 · 2024: $379 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,270 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,270.42 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $562.72 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Pfizer INC. | $546.38 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $489.66 | 2021-2025 | |
| Astellas Pharma US INC | $460.01 | 2022-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $450.70 | 2019-2025 | |
| Organon LLC | $138.82 | 2021-2024 | Nexplanon |
| Exeltis, USA INC. | $131.10 | 2019-2024 | Slynd |
| Evofem Biosciences, INC. | $128.30 | 2021-2025 | Solosec, Phexx, Phexxi |
| Lupin INC. | $125.10 | 2019-2020 | |
| Coopersurgical, INC. | $123.77 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Scynexis, INC. | $116.11 | 2022 | |
| Therapeuticsmd, INC. | $93.77 | 2019-2021 | |
| Myovant Sciences INC. | $91.84 | 2021-2022 | |
| Amgen INC. | $85.77 | 2019-2022 | |
| Mylan Pharmaceuticals INC. | $67.66 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $56.48 | 2019 | |
| Millicent US INC | $52.77 | 2023-2025 | Intrarosa, Femring |
| Covidien LP | $40.85 | 2019 | |
| Dilon Technologies, INC. | $39.79 | 2024 | Hemoblast Bellows |
| Merck Sharp & Dohme LLC | $39.69 | 2019-2020 | |
| Minerva Surgical, INC | $37.78 | 2019 | |
| Sumitomo Pharma America, INC. | $35.42 | 2025 | Myfembree |
| Medtronic, INC. | $32.39 | 2022 | |
| Avion Pharmaceuticals | $26.28 | 2021-2022 | |
| Exact Sciences Corporation | $23.29 | 2025 | The Cologuard Plus Collection Kit |
| Duchesnay USA Incorporated | $23.25 | 2019 | |
| Agile Therapeutics, INC. | $18.88 | 2021 | |
| Mallinckrodt Enterprises LLC | $16.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sargent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.